0000899243-22-003172.txt : 20220125 0000899243-22-003172.hdr.sgml : 20220125 20220125172056 ACCESSION NUMBER: 0000899243-22-003172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220121 FILED AS OF DATE: 20220125 DATE AS OF CHANGE: 20220125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Buell Jennifer CENTRAL INDEX KEY: 0001711184 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 22554805 BUSINESS ADDRESS: BUSINESS PHONE: 781-674-4400 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-21 0 0001840229 MiNK Therapeutics, Inc. INKT 0001711184 Buell Jennifer 149 FIFTH AVENUE, SUITE 500 NEW YORK NY 10010 1 1 0 0 See Remarks Stock Option (Right to Buy) 3.12 2022-01-21 4 A 0 679800 0.00 A 2032-01-21 Common Stock 679800 679800 D Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date. President, Chief Executive Officer By: /s/ Christine Klaskin, attorney-in-fact 2022-01-25